Quarterly report pursuant to Section 13 or 15(d)

Commitments And Contingencies (Details)

Commitments And Contingencies (Details)					1 Months Ended			3 Months Ended		6 Months Ended		12 Months Ended
Commitments And Contingencies (Details)	Aug. 08, 2019 USD ($)	Feb. 16, 2018 unit $ / unit	Nov. 17, 2017 USD ($)	Dec. 18, 2015 USD ($) unit	Aug. 31, 2018 USD ($)	Nov. 30, 2017 USD ($) $ / unit	Aug. 31, 2017 USD ($)	Jun. 30, 2019 USD ($)	Jun. 30, 2018 USD ($)	Jun. 30, 2019 USD ($)	Jun. 30, 2018 USD ($)	Dec. 31, 2018 USD ($)	Mar. 31, 2019 USD ($)	Oct. 31, 2017
Operating Leased Assets [Line Items]
Noncontrolling interest ownership percentage by Noncontrolling Owners														10.00%
Gain on change in fair value								$ 992,350	$ (13,239)	$ 811,948	$ (276,008)
License obligations								1,250,000		1,250,000		$ 1,250,000
Total revenue								4,449,404	$ 4,785,138	9,860,847	9,267,913
Potential future regulatory milestone							$ 20,000,000
Ulesfia Supply Agreement
Operating Leased Assets [Line Items]
Indemnity receivable								(5,200,000)		(5,200,000)			$ 5,200,000
Karbinal Agreement \| TRIS Pharma
Operating Leased Assets [Line Items]
Minimum quantity required \| unit		70,000
Make whole payment (in dollars per unit) \| $ / unit		30
Make whole payment					$ 900,000			400,000		800,000
Accrued make whole payment										1,500,000
Zylera \| Ulesfia Supply Agreement
Operating Leased Assets [Line Items]
Price (in dollars per unit) \| $ / unit						58.84
Management and handling fee (in dollars per unit) \| $ / unit						4.03
Management and handling fee annual price increase						10.00%
Zylera \| Ulesfia Supply Agreement \| Lachlan Pharmaceuticals
Operating Leased Assets [Line Items]
Minimum quantity required \| unit				20,000
Long-term purchase commitment				$ 1,200,000
Minimum royalty						$ 3,000,000
Lachlan Pharmaceuticals \| Ulesfia Supply Agreement
Operating Leased Assets [Line Items]
License obligation								(8,700,000)		(8,700,000)			8,700,000
Royalties payable													$ 400,000
Decrease in royalties payable								(400,000)
Indemnification of pre-acquisition losses (as a percent)						100.00%
Threshold indemnification of legal costs and possible minimum payments						$ 1,000,000
Indemnification of post-acquisition losses, (as a percent)						50.00%
Payments for settlements								2,300,000
CERC-611
Operating Leased Assets [Line Items]
License obligations								1,300,000		1,300,000
License and other revenue
Operating Leased Assets [Line Items]
Total revenue							$ 25,000,000
TRx
Operating Leased Assets [Line Items]
Contingent payments								0		0		0
Potential milestone payment			$ 3,000,000
Milestone One \| TRx
Operating Leased Assets [Line Items]
Business combination gross profit												$ 12,600,000
Minimum \| TRx
Operating Leased Assets [Line Items]
Estimate of possible loss								0		0
Maximum \| TRx
Operating Leased Assets [Line Items]
Estimate of possible loss								3,000,000		3,000,000
Level 3
Operating Leased Assets [Line Items]
Gain on change in fair value										1,277,150	$ 295,341
Level 3 \| Ulesfia Supply Agreement
Operating Leased Assets [Line Items]
Gain on change in fair value								1,300,000		$ 1,300,000
Cost of Sales \| Lachlan Pharmaceuticals \| Ulesfia Supply Agreement
Operating Leased Assets [Line Items]
Gain related to settlement								$ 1,600,000
Subsequent Event \| CERC-611
Operating Leased Assets [Line Items]
Potential milestone payment	$ 7,500,000
Potential milestone revenue threshold	750,000,000
Potential milestone payment two	12,500,000
Potential milestone revenue threshold two	1,300,000,000
Subsequent Event \| Armistice \| CERC-611
Operating Leased Assets [Line Items]
Installment payment	$ 100,000
Payment period	30 days